Profile of:

Jinxian Huang


Full name: Jinxian Huang

Current country: China

Membership level: Full

Type of membership: Member

Number of publications: 20

Calprotectin in psoriatic arthritis: Inflammation and beyond (2023)
https://pubmed.ncbi.nlm.nih.gov/36591902/

Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/36764276/

Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis? (2023)
https://pubmed.ncbi.nlm.nih.gov/37718695/

Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial’. (2023)
https://pubmed.ncbi.nlm.nih.gov/34172501/

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis? (2022)
https://pubmed.ncbi.nlm.nih.gov/35612928/

Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis. (2022)
https://pubmed.ncbi.nlm.nih.gov/36067655/

MRI lesions in SpA: a comparison with noninflammatory back pain using propensity score adjustment method (2022)
https://pubmed.ncbi.nlm.nih.gov/36051632/

Clinical, radiological, and magnetic resonance imaging characteristics of axial spondyloarthritis with late onset. (2022)
https://pubmed.ncbi.nlm.nih.gov/35866796/

Interleukin-17 inhibitor, is it safer than tumor necrosis factor inhibitor? (2021)
https://pubmed.ncbi.nlm.nih.gov/34241967/

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial (2020)
https://pubmed.ncbi.nlm.nih.gov/33195311/

Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al (2020)
https://pubmed.ncbi.nlm.nih.gov/32933918/

Ixekizumab for the treatment of ankylosing spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/32729361/

Placebo responses in ankylosing spondylitis patients worldwide: variations and possible explanations (2020)
https://pubmed.ncbi.nlm.nih.gov/32213079/

Synchronous Acute Acalculous Cholecystitis and Appendicitis Due to Salmonella Group D: A Rare Case Report From China and Review of the Literature (2020)
https://pubmed.ncbi.nlm.nih.gov/33015080/

Successful treatment of tofacitinib in a case with rheumatoid arthritis who experienced hepatitis B virus reactivation induced by tocilizumab and recovered from entecavir rescue therapy (2020)
https://pubmed.ncbi.nlm.nih.gov/34870178/

Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/36465082/

Synchronous Acute Acalculous Cholecystitis and Appendicitis Due to Salmonella Group D: A Rare Case Report From China and Review of the Literature (2020)
https://pubmed.ncbi.nlm.nih.gov/33015080/

Intensity of spinal inflammation is associated with radiological structural damage in patients with active axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/32016167/

Altered expression of microRNAs targeting Dkk-1 in peripheral blood mononuclear cells of patients with ankylosing spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31114438/

Intensity of spinal inflammation is associated with radiological structural damage in patients with active axial spondyloarthritis. (2019)
https://pubmed.ncbi.nlm.nih.gov/32016167/